Last reviewed · How we verify
Antocin Ii (ATOSIBAN)
At a glance
| Generic name | ATOSIBAN |
|---|---|
| Sponsor | Ferring Pharmaceuticals A/S |
| Drug class | atosiban |
| Target | Vasopressin V1a receptor |
| Modality | Recombinant protein |
| Therapeutic area | Other |
| Phase | FDA-approved |
| First approval | 2000 |
Approved indications
- Prevention of Premature Labor
Common side effects
Key clinical trials
- Atosiban in Women With Previous Implantation Failure and Abnormal Uterine Contractions (NA)
- The Effect of Oral Oxytocin and Atosiban on Top-down Attention ( OTAtosiban ) (EARLY_PHASE1)
- The Effect of Oral Oxytocin and Atosiban on Social Attention (EARLY_PHASE1)
- Perioperative Use of Atosiban for Ultrasound-indicated Cerclage to Reduce Spontaneous Preterm Birth(sPTB) (NA)
- Atosiban Versus Placebo in the Treatment of Late Threatened Pre-term Birth (PHASE4)
- In Utero Repair of Myelomeningocele: Atosiban Versus Terbutaline
- The Effect of Selective Oxytocin Receptor Inhibitors on Endometriosis-related Pain (PHASE2)
- Role of Atosiban in Recurrent Implantation Failure
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Antocin Ii CI brief — competitive landscape report
- Antocin Ii updates RSS · CI watch RSS
- Ferring Pharmaceuticals A/S portfolio CI